Rituximab-Associated Progressive Multifocal Leukoencephalopathy: A Twenty-Year Update

Charles L Bennett; Bartlett Witherspoon; Kenneth R Carson

doi:10.1007/978-3-031-04402-1_7

Rituximab-Associated Progressive Multifocal Leukoencephalopathy: A Twenty-Year Update

Cancer Treat Res. 2022:184:103-111. doi: 10.1007/978-3-031-04402-1_7.

Authors

Charles L Bennett¹, Bartlett Witherspoon¹, Kenneth R Carson²

Affiliations

¹ SONAR (Southern Network on Adverse Reactions) Program, University of South Carolina College of Pharmacy, Columbia, SC, 29208, USA.
² SONAR (Southern Network on Adverse Reactions) Program, University of South Carolina College of Pharmacy, Columbia, SC, 29208, USA. Kenneth_R_Carson@rush.edu.

PMID: 36449191
DOI: 10.1007/978-3-031-04402-1_7

Abstract

Progressive multifocal leukoencephalopathy (PML) is a John-Cunningham virus-related central nervous system that is rarely observed in persons treated with the anti-CD20 monoclonal antibody, rituximab.

MeSH terms

Humans
Leukoencephalopathy, Progressive Multifocal* / chemically induced
Rituximab / adverse effects

Substances

Rituximab